A High Rate Of Genetic Parkinsons Makes Israel A Perfect Lab For Finding Ways To Prevent Stop And Even Cure This Fast
Parkinson’s disease is a complex, progressive neurological disorder affecting up to 10 million people. And it is fast growing in prevalence worldwide.
April 11, the birthday of James Parkinson — who first described this syndrome in 1817 — kicks off World Parkinson’s Awareness Week.
The disease is most often diagnosed in people over 60, more often males. Classic symptoms include tremor in about 60 percent of cases, rigidity, poor posture and slow movement.
This happens because clumps of alpha-synuclein protein are aggregating in the brain and autonomic nervous system, damaging dopaminergic cells governing motor control, among other functions. Loss of dopaminergic cells eventually causes the classic Parkinson’s symptoms.
Alpha-synuclein clumping can be triggered by aging, genetic mutations, conditions such as diabetes and hypertension, environmental toxins like pesticides and lifestyle factors like smoking, exercise, diet and mood.
Worldwide, about 10% of cases have a genetic basis. While Israel’s rate of Parkinson’s is no different than in other countries, the percentage caused by genetic mutations is much higher.
“Israel’s high rate of genetic Parkinson’s provides an opportunity to make Israel a global hub for research and development,” he says.
The dope on dopamine
Human Ipsc Studies Of Pd Highlight Converging Molecular And Cellular Pathways Across Genetic Subgroups
Our analysis of 385 iPSC-derived cell lines from 67 published studies reveals that many PD neuronal phenotypes are shared between genetically heterogeneous familial and sporadic patients . Notably, impairments in mechanisms involved in cellular waste recycling, mitochondrial function, neuronal morphology and physiology, and sensitivity to reactive oxygen species are most common across patient lines with varying genetic predispositions . The studies measured cellular phenotypes that occurred either spontaneously or in response to chemicals mimicking cellular aging and stress . It is important to note that the frequency of reported phenotypes in our meta-analysis may be biased because only few studies reported negative results 31,32,36,37,40,45,48,52,59,64,74,76,86. In addition, most cell lines were not systematically phenotyped without prior hypothesis and thus, there is likely to be an ascertain bias in these phenotypes. Less hypothesis-driven multimodal or omics analysis will help to address such bias41,72,76,77,78,79,80,87,90. Phenotypes caused by genomic predispositions allude to crosstalk and impairments in multiple pathways that act collectively to mediate selective degeneration of dopaminergic neurons in the substantia nigra and will be discussed in detail below.
Fig. 4: Phenotypic insights from iPSC studies of Parkinson’s disease.
The Interplay Between Genomic Predispositions And Environmental Factors Leads To Parkinsons
In the mid-1990s, the connection between PD and underlying genetic mutations was established4,5,150. It is now evident that varying degrees of the interplay between genomic predispositions and aging and cellular stressors impose a risk for disease151 . Previous studies have shown vascular insults to the brain, repeated head trauma, neuroleptic drugs, exposure to pesticides, and manganese toxicity increase the risks of developing symptoms of PD152,153,154. In addition, advancing age can also cause a cascade of stressors within the substantia nigra, which weakens the neurons and their ability to respond to further insults155,156. Ultimately, the uniqueness of the interactions between genes and the environment makes the development of a single treatment for PD difficult as they give rise to a spectrum of neuronal phenotypes that can be unique to individual patients . The development of a model with the ability to replicate the genomic and epigenetic aspects of the disease is crucial . As increasing evidence suggests that genetic mutations are key modulators of disease initiation and progression, the identification and understanding of the various genomic predispositions are required for the development of better-targeted treatments to slow the disease progression.
Fig. 1: A combinatorial spectrum of genetic risks, cellular stressors, and brain cell dysfunctions causes Parkinson’s disease.Full size image
Gene4pd: An Integrative Genetic Database And Analytic Platform For Parkinsons Disease
Figure 4. Snapshot of search panel and variant-level implications in Gene4PD. Snapshot of search panel in Gene4PD. Quick search panel and advanced search panel in Gene4PD are illustrated. Snapshot of variant-level implications in Gene4PD. Six sections including “Summary,”“Rare variant,”“Associated SNPs,”“CNVs,”“Differential expression gene,”“Differential DNA methylation,” are set in variant-level implication.
Mitochondrial Recycling In Neurons Is Linked To Genes Mutated In Parkinson’s Disease
2. Nakamura, K . Researchers uncover new mitochondrial recycling pathway that may be linked to Parkinson’s disease. News Medical life Sciences.
3. Li H, Doric Z, Berthet A, Jorgens DM, Nguyen, MK, et al. . Longitudinal tracking of neuronal mitochondria delineates PINK1/ Parkin-dependent mechanisms of mitochondrial recycling and degradation. Science Advances.
4. Ray F Impaired Mitochondrial Recycling Drives Neuron Death in Parkinson’s, Study Indicates. Parkinson’s News Today.
Visit for more related articles at Genetics and Molecular Biology Research
Single Mutation In Recessive Gene Increases Risk Of Earlier Onset Parkinsons Disease
JACKSONVILLE, Fla. — A collaboration of 32 researchers in seven countries, led by scientists at Mayo Clinic’s campus in Florida, has found a genetic mutation they say confers a risk for development of Parkinson’s disease earlier than usual.
The major study, published in Brain, is important because the risk comes from a single mutation in the PTEN-induced putative kinase 1 gene. Investigators had believed that this rare form of Parkinson’s developed only when a person inherited mutations in both PINK1 alleles .
“We know that if you have mutations in both copies of PINK1, age at onset of Parkinson’s will usually be younger than 45. This study showed that if a person inherited a specific mutation in just one PINK1 gene, the disease could develop at about age 55 or so. By contrast, the most common, nonfamilial forms of Parkinson’s develop at about age 65,” says the study’s senior investigator, Wolfdieter Springer, Ph.D., a neuroscientist at Mayo Clinic’s Florida campus.
Genetic studies had suggested that a single mutated PINK1 allele might confer an outsized risk of the developing the disease. It took a “very effective synergetic” effort of clinical, structural and cell biologists, along with geneticists and data from thousands of affected patients, to show how it led to earlier disease development, Dr. Springer says.
“It took a real international collaboration to solve this puzzle,” he says.
Journalists: Sound bites with Dr. Springer are available in the downloads.
Since the identification in 2004 of mutations within the leucine?rich repeat kinase 2 gene in patients with autosomal, dominantly inherited Parkinson’s disease, this gene has been the focus of research on Parkinson’s disease.1 Mutations in the LRRK2 gene and especially the common mutation G2019S may account for 1–2% of familial and 3–6% of sporadic cases of Parkinson’s disease, including those of early and late onset.2 The LRRK2 gene is situated on chromosome 12p11.2–q13.1 and encodes a large protein named dardarin. Dardarin contains several functional domains, including a leucine?rich repeat domain, WD40, renin–angiotensin system/guanosine triphosphatases and kinase domains. The presence of the leucine?rich repeat and WD40 domains suggests a role in protein–protein interaction. In addition, function was demonstrated kinase for dardarin in vitro.3
Several common exonic exchanges and intronic single?nucleotide polymorphisms were identified. Of three patients who carried mutations in heterozygous state, two harboured the common mutation G2019S and one patient showed a novel mutation A1151T .
People Who Already Have Pd: Should I Get Tested And What Do I Do With The Results
Up until recently, even people with PD with a very extensive family history of PD would not necessarily receive genetic testing because there were no clear uses for the results. There has been research directed at figuring out whether PD caused by or associated with certain mutations have particular clinical characteristics . However, there remains so much variability in clinical characteristics even among people with the same PD mutation, that there are still no clear practical implications in knowing whether a PD patient harbors a particular mutation. There is also, so far, no difference in treatment or management of PD whether or not the patient harbors one of the known mutations. That may change however, with the advent of clinical trials that target particular mutations.
There are two genes that have received particular attention recently because medications are being developed that target those with mutations of these genes.
GBAis a gene that increases the risk of developing PD. The gene encodes for the GBA enzyme, a protein used by the body to break down cellular products. Having two abnormal GBA genes causes Gaucher’s disease, which is characterized by the buildup of these cellular products resulting in fatigue, bone pain, easy bleeding and an enlarged spleen and liver. When a person inherits only one abnormal gene, he or she does not develop Gaucher’s disease, but does incur a small increased risk of PD. Most people with one mutated GBA gene do not develop PD.
Are Genes Responsible For Monogenic Disorders Also Susceptibility Factors
Associations detected by screening candidate genes in controls and patients cannot always be replicated in follow-up studies, and few candidate genes were confirmed in meta-analysis, because of potential biases and confounding factors, including population stratification, small sample size, misclassification and/or inappropriate statistical methods. Polymorphic variants in SNCA and LRRK2 genes, and heterozygous mutations in the GBA gene, however, have been validated as genetic susceptibility factors .
Nucleotide polymorphisms located close to the promoter region and throughout SNCA have been associated with sporadic PD, although much of the data is equivocal . Rep1 , a mixed nucleotide repeat, 10 kb upstream of the translational start of SNCA , has been confirmed as a risk factor , and synergy between an SNCA variant and a polymorphism in microtubule-associated protein tau , each of which increases the risk for the development of PD, has been detected . The combination of risk genotypes in SNCA and MAPT doubles the risk of PD, further supporting the notion that the related pathways contribute to neurodegenerative diseases . The risk associated with Rep1 does not interact, however, with herbicide exposure, an independent risk factor in PD .
Genetic Predispositions Reducing Differentiation Yield Of Mda Neurons
In vitro neural development was impaired in neural lines derived from patients carrying LRRK2, PRKN, SNCA, and sporadic mutations43,49,74,93. In four independent studies, the differentiation potential of neural progenitor cells derived from patients was significantly reduced, demonstrated by low yields of neurons in comparison with control lines43,49,74,81,94. A recent review presented the idea that PD is attributed to significant neurodevelopmental defects, which may increase the susceptibility for disease onset224. If confirmed, identifying genetic predispositions that contribute to early developmental defects in iPSC-PD may assist the development of novel PD therapies. However, these phenotypes may appear in conflict with other studies53,55,76 capable of generating functional neurons from cell lines with similar mutations. The differences could be due to varying protocols, which may be more or less stressful for the cells.
Will Findings From Pd Ipsc Models Translate To Human Clinical Trials
Given the apprehensions that in vitro studies may be too artificial, human iPSC-derived neural progenitors may be transplanted into animal brains244,245,246,247. Besides ethical barriers, xenografts also raise the possibility that the healthy host tissue compensate for the impairment of the transplanted cells. Yet, if the phenotypes observed in vitro are recapitulated in vivo, pharmacological treatments could be assessed in a systemic environment, with much more realistic dosage and administration methods.
Pesticide Exposure Increases Risk Of Developing Parkinsons Disease
Environmental triggers like occupational exposure to pesticides can prompt Parkinson’s disease in individuals with or without the genetic precursor.
The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by . It’s free.
Research at the University of California San Francisco finds that pesticide exposure increases the risk of developing Parkinson’s disease , regardless of whether disease onset is idiopathic or genetic . Although the exact etiology of PD remains unknown, epidemiological and toxicological research repeatedly identifies exposure to pesticides, as well as specific gene-pesticide interactions, as significant adverse risk factors that contribute to PD.
Furthermore, this study, “Gene Variants May Affect PD Risk After Pesticide Exposure,” suggests that environmental triggers like occupational exposure to pesticides can prompt PD in individuals with or without the genetic precursor.
Parkinson’s disease is the second most common neurodegenerative disease, with at least one million Americans living with PD and about 50,000 new diagnoses each year. The disease affects 50% more men than women and people with PD have a variety of symptoms, including loss of muscle control and trembling, anxiety and depression, constipation and urinary difficulties, dementia, and sleep disturbances. Over time, symptoms intensify, but there is no current cure for this fatal disease.
How Environmental Factors And Aging Can Be Recapitulated In Vitro
An obvious limitation of in vitro models is the lack of environmental context. The influence of nongenetic factors is not recapitulated in the basal phenotype of patient-derived neurons. For example, the influence of head trauma of a boxer with sporadic PD will not be recapitulated by default in reprogrammed neurons. An alternative would be to transplant the patient-derived neurons in animals and simulate the trauma on the animal. Similarly, influence of decades of aging of the human brain is difficult to reproduce in vitro in a few months within the boundaries of feasible experimental design. Brains in a dish will always be an imperfect experimental model. However, many tricks can be used to recapitulate the environmental and aging stress in vitro. Table 2 summarizes a list of reagents that have already been used in iPSC neuronal culture to mimic oxidative stress, proteostatic stress, mitochondrial stress, synaptic stress, ER stress, inflammation, and cellular aging. An interesting example is progerin, a truncated form of lamin A associated with premature aging. Increasing the expression of progerin in iPSC neurons can recapitulate at least some aspect of cellular aging in vitro71. Human iPSC-derived dopamine neurons overexpressing progerin displayed specific phenotypes such as neuromelanin accumulation. In addition, PD patient-derived neurons revealed disease-related phenotypes that required both genetic susceptibility and induced-aging in vitro71.
Gene4pd: A Comprehensive Genetic Database Of Parkinsons Disease
- 1National Clinical Research Center for Geriatric Disorders, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China
- 2Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- 3Mobile Health Ministry of Education—China Mobile Joint Laboratory, Xiangya Hospital, Central South University, Changsha, China
- 4Center for Medical Genetics, Hunan Key Laboratory, School of Life Sciences, Central South University, Changsha, China
- 5Department of Pathogen Biology, School of Basic Medical Sciences, Central South University, Changsha, China
Neuroinflammation Exacerbates Neurodegeneration In Sporadic Pd
Midbrain neurons derived from sporadic patients showed increased susceptibility to the effects of adaptive immune cells72. Sporadic patient neuronal lines co-cultured with T-lymphocytes exhibited substantial signs of cell death mediated by IL-17–IL-17R signaling and activation of NFkB72. Similarly, IL-17 treatment resulted in increased neuronal death72. Inflammation in the central nervous system and periphery are key hallmarks of PD220. Increasing evidence implicates the role of microglia in neuronal loss, though the underlying mechanisms remain to be determined221,222. RNA-seq analysis of astrocytes derived from LRRK2-G2019S iPSCs highlighted dysregulation in genes involved in the extracellular matrix, which may reduce the neuroprotective capacity of astrocytes in PD78. Investigating the role of neuroinflammation in patient-derived microglia may also contribute to the understanding of the selective vulnerability of mDA neurons in sporadic and late-onset PD223.
The Verification Of Functional Correlation And Pag Network
We performed a permutation test to evaluate the interconnectivity and functional correlation among the 124 PAGs as described in our previous study . To ensure a reasonable level of analysis, we constructed a protein-protein interaction network using the STRING v 11.0 database1 with a confidence score greater than 0.4. Specifically, we randomly simulated 1,000,000 permutation tests to evaluate the interconnectivity among high-confidence/strong genes, and among suggestive genes, as well as to determine the connectivity between these two classes of PAGs. Then, the 124 PAGs were selected to construct an interconnected PPI network based on the STRING online analysis platform. Additionally, the functional networks were clustered by multiple biological processes of Gene Ontology 2.
Genetic Principles And Exceptions Thereof In Familial Pd
The majority of PD cases are sporadic, i.e., only about 10% of patients report a positive family history . Out of the six genes unequivocally linked to heritable, monogenic PD, mutations in SNCA , and LRRK2 are responsible for autosomal-dominant PD forms, and mutations in Parkin , PINK1 , DJ-1 , and ATP13A2 are accountable for PD that displays an autosomal recessive mode of inheritance.
In general, the inheritance patterns of human disorders are identified by examining the way the disorders are transmitted in the family of the index patient. Such a pedigree analysis requires a careful assembly of the disease records of the family members over several generations, and if possible, examination and sample collection from affected and unaffected individuals from the pedigree. All of the currently known monogenic PD forms are autosomal , which means that they are linked with regions on autosomes .
Pedigree of a PD family that comprises affected members with and without the LRRK2 p.G2019S mutation. Five mutation carriers are unaffected, showing reduced penetrance, two mutation carriers are affected with dystonia, showing variable expressivity, and one affected family member does not have the p.G2019S mutation in LRRK2. Black symbols – affected individuals; white symbols – unaffected individuals; half-filled symbols – individuals with dystonia; + – mutation carriers.
Which Gene Mutations May Be Related To Parkinson Disease
The identification of a few families with familial Parkinson disease sparked further interest in the genetics of the disease. In one large family in Salerno, Italy, 50 of 592 members had Parkinson disease; linkage analysis incriminated a region in bands 4q21-23, and sequencing revealed an A-for-G substitution at base 209 of the alpha-synuclein gene. Termed PD-1, this mutation codes for a substitution of threonine for alanine at amino acid 53. These individuals were characterized by early age of disease onset , rapid progression , lack of tremor, and good response to levodopa therapy. Five small Greek kindreds were also found to have the PD-1 mutation.
In a German family, a different point mutation in the alpha-synuclein gene confirmed that mutations in the alpha-synuclein gene can cause Parkinson disease. A few additional familial mutations in the alpha-synuclein gene have been identified and are collectively called PARK1. It is now clear that these mutations are an exceedingly rare cause of Parkinson disease.
A total of 18 loci in various genes have now been proposed for Parkinson disease. Mutations within 6 of these loci are well-validated causes of familial parkinsonism. Inheritance is autosomal dominant for SNCA and LRRK2 . Inheritance is autosomal recessive for PRKN, DJ1, PINK1, and ATP13A2. In addition, polymorphisms within SNCA and LRRK2, as well as variations in MAPT and GBA, are risk factors for Parkinson disease.
Learning From Genetic Analyses Of Pd Casecontrol Studies
We analyzed the reports from 12 international studies94,157,158,159,160,161,162,163,164,165,166,167, totaling 5650 persons living with PD in North America, Europe, and Australia. We confirmed that globally only 15% of patients report a family history of PD symptoms, while the remaining 85% of the PD population are classified as sporadic PD . However, the distinction between genetic predispositions in familial and sporadic PD is blurry. No single-gene mutation in PD has a 100% penetrance. Instead, most likely, multiple genetic risk factors act in synergy to increase the chances of both familial and sporadic PD. Such genetic susceptibilities interplay with aging and environmental factors in both familial and sporadic PD.
Fig. 2: The genomics of Parkinson’s disease: prevalence and penetrance.
a In the world-wide population of people living with PD, ~85% of PD cases are sporadic and the remaining are familial . b Genetic mutations occur at low and varying frequencies in the PD world population . Data represented as the mean±SEM. c GWAS data suggests risk variants in fPD genes tend to be less prevalent in PD cases . d Single nucleotide polymorphisms in over 44 genomic regions show significant association to PD. Each point presents an independent SNP hit associated with PD.
Why Genetic Testing For Parkinsons Disease Is Complex:
- There are many genes that are associated with the development of PD. This list continues to grow as more genes are discovered. Testing of only some of these genes is available in commercial labs.
- The majority of people with PD, even those with a family history of PD, do not harbor one of these identified abnormal genes. The genetic contribution to PD in these people is yet to be discovered.
- For a particular gene there may be a number of different mutations associated with disease, some of which are more common than others. Commercial testing may identify only the most common of the mutations, and therefore not capture everyone who carries a disease-causing mutation.
- Conversely, only particular mutations in a gene may be associated with disease. Commercial testing may identify changes in a gene that may not have clinical consequences. This can be confusing for patients who even after genetic testing may not know whether they harbor a disease-causing mutation.
- Different mutations can be enriched in different ethnic populations. For example, Ashkenazi Jews and North African Berbers have an increased risk of carrying Leucine rich repeat kinase 2 mutations. Glucocerebrosidase mutation frequency also varies greatly with ethnicity and is also increased among Ashkenazi Jews.
In addition to the above, it is important to realize that not all genes associated with PD contribute to disease in the same way:
Genetic Susceptibility Factors In Parkinson’s Disease
Monogenic forms represent less than 10% of PD in most populations. The vast majority result from complex interactions among genes and between genes and environmental factors. Genetic variations may be susceptibility factors or disease modifiers, affecting penetrance, age at onset, severity and progression. High-density arrays of single nucleotide polymorphisms permit the identification of susceptibility factors in genome-wide association studies, in which the frequencies of putative risk alleles are compared in patients and controls.
Gene Mutation Linked To Cause Of Parkinson’s Disease
Finding May Eventually Make Genetic Testing Possible
Jan. 18, 2005 — A change in just one gene may affect the risk of Parkinson’s disease. That could lead to genetic testing for Parkinson’s, say scientists.
The gene in question is the LRRK2 gene. It’s the topic of three studies in the Jan. 18 online edition of The Lancet.
A single mutation in the LRRK2 gene occurs in about 5% of inherited Parkinson’s cases and 2% of isolated cases, experts report in The Lancet. The mutation was seen in familial Parkinson’s disease as well as in patients without a family history of the disease.
In Parkinson’s disease, the brain’s movement signals to the rest of the body are garbled. That can cause tremors and trouble with movement and balance, although symptoms vary greatly from person to person.
Parkinson’s usually strikes after age 50, although it’s sometimes seen in people as young as 30. It occurs in more than 1% of people age 55 or older and 3% of those older than 75. Of the age-related nerve degenerative conditions, only Alzheimer’s disease is more common.
Several abnormal genes have been linked to Parkinson’s development but haven’t been flagged as a cause of the disease. Most researchers believe that both genetics and the environment play a role in the development of the disease. However, the role of genetics is not clear.
Identification Of New Genes And Risk Factors For Pd
New PD-linked genes or PD risk factors can be identified by gene mapping or candidate gene approaches. Gene mapping in human diseases is the localization of genes underlying the clinical phenotypes of the disease on the basis of correlation with DNA variants , without the need for prior hypotheses about biological function. Genetic mapping methods include linkage analysis and genome-wide association studies. Alternatively, based on their known function, levels of expression, or mode of interaction , some genes can be considered plausible candidates, and as such, tested for in cohorts of patients.
Aao Is Associated With Multiple Genetic Components
The integrated genetic data and AAO data from the Gene4PD database provide an unprecedented opportunity to comprehensively identify the vital association between the AAO and PAGs on a large scale. Therefore, we analyzed 31 PAGs with more than five AAO items in each gene . After sorting by the median AAO of each gene, we found that 10 genes were associated with a juvenile-onset , 11 genes were associated with an early-onset , whereas another 10 genes were associated with a late-onset . Although different PAGs had specific AAO characteristics, we noted that there were large differences in the AAO for some genes, such as for PRKN, PINK1, SNCA, and LRRK2, suggesting that there are other factors that contribute to the AAO.
Figure 3. Association between Parkinson’s disease-associated genes and age at onset. The association between age at onset and 31 Parkinson’s disease-associated genes with more than five AAO items. The genes shown are sorted according to the median AAO or each gene. Association between AAO and 10 Parkinson’s disease-associated genes with more three loss-of-function variants and deleterious missense variants.
Who Should Consider A Genetic Test For Parkinsons
There are two groups of people who might consider getting genetic testing and we will discuss each group separately.
Genetic testing for PD is a common request and a number of commercial labs perform panels of genetic testing for PD. You may ask: “How can I test myself for Parksinon’s?” Whether you’re considering getting a genetic test through your doctor, or performing one at home, it’s important to note that at-home test don’t map the entire gene for mutations. Genetic testing through your doctor will test for GBA, PARK7, SNCA, LRRK2, parkin and PINK1.
Both groups are faced with two questions: Should I get genetic testing? And if so, what should I do with the results? Before we address these two questions, we need to learn more about the complexity of genetic testing in PD.
Epigenomic Alterations Linked With Pd In Patient
The ability to capture unique epigenomic alterations associated with PD remains an important challenge. Reprogramming fibroblasts to iPSCs may erase age-associated225 and naive epigenetic signatures which could contribute to sporadic PD pathophysiology226. However, an epigenetic phenotype was reported in iPSC-derived PD patient neurons79,89. Neuronal lines derived from LRRK2 and sporadic patients exhibited epigenomic alterations when compared with healthy controls79. Hypermethylation was prominent in gene regulatory regions associated with the downregulation of transcription factors FOXA1, NR3C1, HNF4A, and FOSL279. Interestingly, LRRK2 mutant and sporadic PD patient neurons shared similar methylation patterns, which were absent in the original donor fibroblasts79. A spontaneous increase in the number of DNA strand breaks and genomic damage89 in PD patient-derived neurons could indirectly impact genomic regulation.
Genomic Data Integration And Pag Prioritization
Through systematic review and curation of multiple lines of public studies, we reviewed more than 3,000 publications, 487 of which met the quality control and collection criteria. Genetic information such as gene symbols, chromosomes, locations, reference base, altered base, and hereditary modes were collected, and other basic information and clinical data, including sample ID, PubMed ID, methods of detecting variants, country, race, gender, AAO, functional study, subtype of disease, detail description of clinical phenotypes, and sporadic/familiar types, were also integrated. We catalogd five types of genetic data related to PD: 2,252 rare variants, including 954 non-redundant rare variants, in 226 genes from 327 available publications; 139 CNVs in 34 genes from 94 publications; 1,237 associated SNPs in 640 genes from 42 studies; 2,926 DEGs from 8 publications; 657 DMGs from 7 publications . Specifically, for the collected genetic variants, we identified 334 rare LoF, 1,328 rare Dmis variants, 485 rare Tmis variants, and 105 other remaining variants based on standard annotations.
Table 1. Prioritized associated genes in Gene4PD.
Generating Relevant Neuronal Cell Types For Pd
The cellular reprogramming toolbox for researchers is rapidly expanding and includes a panoply of neuronal differentiation protocols to generate cells representing various brain regions21. PD is a debilitating motor system disorder resulting from the selective degeneration of midbrain dopamine neurons located in the substantia nigra pars compacta. Protocols have been established to specifically generate dopaminergic neurons and brain cells with a midbrain molecular profile195,196.